Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...
Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...
atea pharmaceuticals宣布公司的Bemnifosbuvir和Ruzasvir联合方案，治疗丙型肝炎病毒的2期研究达到了安全性和主要终点...
Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And Sustained Virologic Response At 12 Weeks Post-treatment
atea pharmaceuticals宣布公司对贝德替非韦和鲁扎斯韦联用治疗丙型肝炎的II期研究，在治疗后12周达到了安全性和持续病毒学应答的主要终点
资讯热榜
更新时间